Substance-Related Disorders

2
Pipeline Programs
1
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Alkermes
AlkermesDUBLIN 4, Ireland
2 programs
1
1
naltrexone for extended release injectable suspensionPhase 41 trial
RDC-0313 + BuprenorphinePhase 11 trial
Active Trials
NCT01046539CompletedEst. Jul 2010
NCT01563718CompletedEst. Aug 2015

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Alkermesnaltrexone for extended release injectable suspension
AlkermesRDC-0313 + Buprenorphine

Clinical Trials (2)

NCT01563718Alkermesnaltrexone for extended release injectable suspension

Pre-Release VIVITROL for Opioid Dependent Inmates

Start: Mar 2012Est. completion: Aug 2015
Phase 4Completed
NCT01046539AlkermesRDC-0313 + Buprenorphine

Phase 1 Study to Evaluate RDC-0313 Coadministered With Buprenorphine to Opioid-Experienced Healthy Adults

Start: Jan 2010Est. completion: Jul 2010
Phase 1Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space